News

€17m for pan-European PPP
Enlarge image

BusinessItalySwitzerland

€17m for pan-European PPP

29.10.2012 - It is a significant upgrade for Italian basic research: British-Swiss Shire collaborates with Telethon Foundation on rare disease drugs.

It is a company first for British Shire Pharmaceuticals plc. Despite having had strong ties with academia for a while, the pharma firm has also finally partnered up in a public-private partnership (PPP) with an academic institution for the first time. Last week Swiss Shire Human Genetic Therapies – Shire’s stock corporation from Nyons – and Italian Telethon Foundation entered a long-term collaboration in discovering new medicines against rare diseases. In particular, Shire will spend over the next five years €17m on research on 13 mainly undisclosed indications. The only thing known is that a number of different lysosomal storage disorders and neurodegenerative disorders are among them. With this long-term collaboration, the British hope to boost their early stage pipeline. The terms for Shire picking up a ripening project and eventually bringing it through mid and late clinical stages are still under discussion.

Telethon general manager Francesca Pasinelli underscored the importance of the deal for her foundation: „For a not-for-profit organisation like ours, this alliance represents an opportunity to fulfil the promise made to patients and donors who have been supporting us.“ Most of the research will be carried out at the Telethon Institute of Genetics and Medicine (TIGEM) in Naples. The institute’s research strength lies in gene therapeutics.

Earlier this year Shire launched another early-stage programme together with zinc-finger-technology torchbearer Sangamo Bioscience (tackling haemophilia). While Shire now enters virgin soil with a public-private partnership, Telethon already has some experience in this respect. Since 2010 the foundation – together with GlaxoSmithKline – has been developing a gene therapy for the devastating immune deficiency ADA-SCID.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/eur17m-for-pan-european-ppp.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.43 EUR13.20%
  • EVOLVA1.55 CHF4.73%
  • BASILEA122.20 CHF4.44%

FLOP

  • MOLOGEN5.38 EUR-4.78%
  • BIOFRONTERA1.84 EUR-3.16%
  • MORPHOSYS74.76 EUR-3.01%

TOP

  • WILEX3.43 EUR75.0%
  • BASILEA122.20 CHF16.9%
  • FORMYCON16.70 EUR16.8%

FLOP

  • SANTHERA94.55 CHF-10.4%
  • STRATEC BIOMEDICAL43.49 EUR-7.5%
  • BIOFRONTERA1.84 EUR-5.6%

TOP

  • SANTHERA94.55 CHF2330.6%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 27.02.2015